There are 398 resources available
LBA3 - Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: final results of the SOLTI TOT-HER3 window of opportunity trial
Presenter: Aleix Prat
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Chemotherapy strategies for early TNBC
Presenter: Giuseppe Curigliano
Session: Neo-adjuvant and adjuvant triple negative breast cancer (TNBC)
Resources:
Slides
Webcast
KARMA study
Presenter: Per Hall
Session: Risk based prevention and screening in breast cancer
Resources:
Webcast
162O - Primary analysis from DS8201-A-U105: A 2-part, open label, phase 1b trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Presenter: Erika Hamilton
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Optimising loco-regional treatment in early TNBC
Presenter: Sherko Kuemmel
Session: Neo-adjuvant and adjuvant triple negative breast cancer (TNBC)
Resources:
Slides
Webcast
MyPeBS study
Presenter: Suzette Delaloge
Session: Risk based prevention and screening in breast cancer
Resources:
Slides
Webcast
Invited Discussant LBA3 and 162O
Presenter: Rebecca Dent
Session: Proffered Paper session 1
Resources:
Slides
Webcast
163O - Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Presenter: Giuseppe Curigliano
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Can we de-escalate treatment options in selected patients?
Presenter: Javier Cortes
Session: Neo-adjuvant and adjuvant triple negative breast cancer (TNBC)
Resources:
Slides
Webcast
Feasibility and acceptability of risk based screening including reduced screening in low risk women
Presenter: D. Evans
Session: Risk based prevention and screening in breast cancer
Resources:
Slides
Webcast